Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.60 |
| ▸ | CA2 | P00918 | 6/20 | 0.60 |
| ▸ | CA7 | P43166 | 6/20 | 0.60 |
| ▸ | CA9 | Q16790 | 6/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.60 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16726998 | 0.89 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2568060 | 0.88 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15054077 | 0.88 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9751375 | 0.84 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1107694 | 0.84 | CA1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16729318 | 0.84 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16606258 | 0.83 | CA12 (0.75) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15054565 | 0.82 | MAPT (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21257515 | 0.80 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4368311 | 0.80 | CA12 (0.66) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102781583-B | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEM PATENTS INC | 2015-07-22 | — | — | CN | disclosed |
| EP-2866936-A1 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| CN-104394987-A | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEM PATENTS INC | 2015-03-04 | — | — | CN | disclosed |
| US-8809563-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809563-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809563-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014004089-A1 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2533899-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-11-15 | — | — | US | disclosed |
| CN-102781583-A | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEM PATENTS INC | 2012-11-14 | — | — | CN | disclosed |
| US-8237003-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8237003-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8237003-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2011100022-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100022-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | MGLL, FASN, FDFT1 | CA12 2431/4885CA1 3621/4885CA2 3877/4885 |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | MGLL, FASN, MSMO1 | CA12 1380/4885CA1 1589/4885CA2 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.